Slow Transit Constipation Clinical Trial
Official title:
Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation: a Randomized Controlled Study
The purpose of this study is to compare the effect of freeze-dried, capsulized FMT and fresh FMT in adults with slow transit constipation.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Chronic constipation according to Rome III criteria, defined as two or fewer spontaneous, complete bowel movements (SCBMs) per week for a minimum of 6 months; Age = 18 years; BMI: 18.5-25 kg/m2; Slow colonic transit confirmed by colonic transit test (colonic transit time (CTT) > 48 hours); Normal anorectal manometry, with no evidence of dyssynergia and confirmed ability to expel rectal balloon; No radiographic evidence of functional (i.e. pelvic floor dyssynergia) or anatomical (i.e. significant rectocele and intussusception) impediment to the expulsion of the radio-opaque contrast; Disease duration > 1 year; Traditional treatment with dietary modification, laxatives (including osmotic and stimulant laxatives), and biofeedback tried over the past 6 months without success; Exclusion Criteria: Bowel constipation due to innate factor (i.e. megacolon) or secondary interventions (i.e. drugs, endocrine, metabolic, neurologic or psychologic disorders); History or evidence of gastrointestinal diseases (i.e. obstruction, cancer, inflammatory bowel diseases) ; Previous abdominal surgery, except cholecystectomy, appendicectomy, tubal ligation and cesarean section; Previous proctological or perianal surgery; A constipation condition meeting the Rome III criteria for IBS or functional abdominal pain syndrome; Pregnant or breast-feeding women; Infection with enteric pathogen; Usage of probiotics, prebiotics and/or synbiotics within the last month; Usage of antibiotics and/or PPIs within the last 3 months; Smoking or alcohol addiction within the last 3 months; Uncontrolled hepatic, renal, cardiovascular, respiratory or psychiatric disease; Disease or therapy with drugs (i.e. antidepressants, opioid narcotic analgesics, anticholinergics, calcium antagonists, nitrates, antimuscarinics) that, in the opinion of the investigator, could affect intestinal transit and microbiota. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jinling Hospital, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients having on average three or more SCBMs/week | Proportion of patients having on average three or more spontaneous, complete bowel movements (SCBMs) per week was evaluated at week 4 and 12. | 3 months | No |
Secondary | Mean number of bowel movements per week | Patients kept daily diaries about times of bowel movements each day. | 3 months | No |
Secondary | Characteristics of bowel movements | Patients kept daily diaries about stool consistency and degree of straining severity during defecation. | 3 months | No |
Secondary | Constipation-related symptoms assessments | Constipation-related symptoms were evaluated using the validated Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire at week 4 and 12. | 3 months | No |
Secondary | Quality-of-Life assessments | Quality-of-Life was evaluated using the validated Patient Assessment of Constipation Quality of Life (PAC-QOL) self-report questionnaire at week 4 and 12. | 3 months | No |
Secondary | Colonic transit time measurements | Colonic transit time (CTT) was measured at week 4 and 12 with the Metcalf method. | 3 months | No |
Secondary | Usage of laxatives or enemas as rescue medication | If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax). If ineffective, enema was used. Patients kept daily diaries about the rescue medication when used. | 3 months | No |
Secondary | Adverse events | Adverse events include fever, diarrhea, abdominal pain, increased bloating, borborygmi, flatulence, nausea, vomiting, nasopharyngitis, and any other disorders. | 3 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02844426 -
Effect of a Synbiotic on Symptoms of Patients With STC
|
Phase 2 | |
Recruiting |
NCT02526849 -
Efficacy and Safety of Fecal Microbiota Transplantation for Slow Transit Constipation
|
Phase 2 | |
Recruiting |
NCT05352074 -
STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation
|
N/A | |
Recruiting |
NCT02291354 -
Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation
|
Phase 2 | |
Active, not recruiting |
NCT02301221 -
Effect of Fecal Microbiota Transplantation in Slow Transit Constipation
|
Phase 2 | |
Active, not recruiting |
NCT05718505 -
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
|
N/A | |
Recruiting |
NCT02984969 -
Using 16S rRNA Gene Sequencing Analysis Intestinal Microbiota in Constipation Patients
|
N/A |